# Phase III OASIS-4 Data Show Elinzanetant Improves Menopausal Symptoms and Sleep in Breast Cancer Survivors on Hormone Therapy

> clinical trial · REPORTED · 2026-06-01

Phase III OASIS-4 trial data presented at ASCO 2026 showed that elinzanetant, an NK1/NK3 receptor antagonist, improved quality of life and reduced sleep disturbance and hot flashes in women ages 18 to 70 taking hormone therapy for HR-positive breast cancer. Elinzanetant is the first drug of its class approved by the FDA for breast cancer-related vasomotor symptoms, representing a major advance in survivorship care.

About Elinzanetant (Bayer/OASIS-4) — sector event: Elinzanetant is a non-hormonal, once-daily oral NK1/NK3 receptor antagonist developed by Bayer for the treatment of vasomotor symptoms including hot flashes and sleep disruption in women undergoing hormone therapy for breast cancer.

- Company: Elinzanetant (Bayer/OASIS-4) — sector event
- Sector: oncology
- Primary source: https://www.lbbc.org/news/action-in-survivorship-reducing-risk-of-recurrence-and-improving-quality-of-life-asco-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.